CORAL GABLES, FL / ACCESSWIRE / August 2, 2017 / Stocks are hitting all-time highs this summer and under the micro-scope has been volatility and price gains. Increased speculation in the markets caused by US politics has lended a hand to the market's aggressive spikes. Curious bottom feeders continue to watch for beaten down stocks and many are looking for small cap stocks to be the ones to target.
Jumps in trading volumes this summer have added to the expectation that this bull market is not over yet. Some of the top trending stocks this summer have been found in the technology, biotech and consumer sectors with a lot of focus on new leadership & corporate milestones.
GT Biopharma (OXIS), for example, announced today that it has added people to its FDA trial. In a press release the company stated that it has added four patients have been enrolled in the company's Food and Drug Administration-approved (FDA) Phase 2 clinical trial of its promising cancer therapy, OXS-1550. From July 28 to August 2, shares of the biotech stock have increased in price from under two cents to as high as $0.0309. Full Report on GT Biopharma (OXIS)
Another stock to watch in August is a healthcare stock, Medical Transcription Billing, Corp. (NASDAQ: MTBC). The company is a leading provider of proprietary, cloud-based healthcare IT solutions and services. The company is set to release its second quarter financial results for the three months ended June 30, 2017 before the market opens on Thursday, August 3, 2017. From July 31 to August 2, the stock has already moved up from $1.24 to morning highs of $1.93 on the 2nd ahead of these earnings results.
CorMedix Inc. (CRMD) has also seen an active market in August. The stock has been in a sharp downtrend for weeks but after hitting lows of $0.35, shares of the stock rose to as high as $0.45 on August 2nd. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. On August 2nd the biopharmaceutical firm said it held "favorable correspondence" with the Food and Drug Administration over proposed revisions to an ongoing phase 3 trial of Neutrolin in bloodstream infections, and reaffirmed its belief that it will be able to complete the study by the end of 2018.
About BiotechStocks.com
BiotechStocks.com is owned by MIDAM Ventures LLC., a Florida corporation that has been compensated $150,000 by OXIS International Inc. (OXIS) for a period beginning August 1, 2017 and ending September 1, 2017 to publicly disseminate information about OXIS International Inc. (OXIS). We own zero shares. Full Disclaimer Here.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither BTS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://biotechstocks.com
NO WARRANTY
BTS, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Contact:
news@biotechstocks.com
SOURCE: BiotechStocks.com
